复方芩兰口服液对急性上呼吸道感染患者炎症因子的影响

Effect of compound qinlan oral liquid on inflammatory factors in patients with acute upper respiratory tract infection

目的分析复方芩兰口服液对急性上呼吸道感染患者炎症因子的影响。方法选取2019年8月至2020年8月130例淄博市妇幼保健院收治急性上呼吸道感染患者,随机分为观察组(n=65)与对照组(n=65),观察组采取常规西药联合复方芩兰口服液治疗,对照组采取常规西药治疗。比较两组患者临床治疗效果、治疗前后炎症因子水平变化、症状改善时间(咳嗽、发热、咽痛症状)及不良反应发生率。结果观察组总有效率显著高于对照组(95.4%vs 80.0%,P<0.05);两组患者治疗前CRP、IL-6水平比较,差异无统计学意义[(12.31±3.20)mg/L vs(12.20±3.41)ng/L,P>0.05;(5.61±1.22)μg/L vs(5.82±1.41)μg/L,P>0.05];观察组患者治疗后CRP、IL-6水平明显低于对照组(3.20±1.00 vs 7.52±2.10),P<0.05;1.41±0.31 vs 2.32±0.43,P<0.05)。观察组咳嗽、发热、咽痛症状改善时间较对照组短[(1.68±0.24)d vs(2.53±0.37)d,P<0.05;(1.26±0.13)d vs(1.94±0.07)d,P<0.05;(1.44±0.36)d vs(2.74±0.63)d,P<0.05),对照组、观察组不良反应发生率分别为3.08%、4.62%,组间对比,差异无统计学意义(P>0.05)。结论复方芩兰口服液能够提高急性上呼吸道感染的临床疗效,降低患者血清炎症因子水平,症状改善时间短,不良反应发生率低,值得推广使用。

Objective To analyze the effect of compound qinlan oral liquid on inflammatory factors in patients with acute upper respiratory tract infection(AURI).Methods 130 patients with AURI admitted to Zibo Maternal and Child Health Hospital from August 2019 to August 2020 were selected.They were randomly divided into the observation group(n=65)and the control group(n=65).The observation group was treated with conventional western medicine combined with compound qinlan oral liquid,while the control group was treated with conventional western medicine.The clinical efficacy,changes of inflammatory factor level before and after treatment,symptom improvement time(cough,fever and pharyngeal pain)and the incidence rate of adverse reactions of the two groups were compared.Results The total effective rate was significantly higher in the observation group than that in the control group(95.4%vs 80.0%,P<0.05).There were no significant differences in CRP and IL-6 levels between the two groups before treatment(12.3±3.2 vs 12.2±3.4,P>0.05;5.6±1.2 vs 5.8±1.4,P>0.05).After treatment,the levels of CRP and IL-6 were significantly lower in the observation group than those in the control group(3.2±1.0 vs 7.5±2.1,P<0.05;1.4±0.3 vs 2.3±0.4,P<0.05).The time to improve cough,fever and pharyngeal pain was shorter in the observation group than that in the control group(1.68±0.24 vs 2.53±0.37,P<0.05;1.26±0.13 vs 1.94±0.07,P<0.05;1.44±0.36 vs 2.74±0.63,P<0.05).The incidence of adverse reactions was 3.08%and 4.62%in the control group and the observation group,respectively,and there was no significant difference between the two groups(P>0.05).Conclusion Compound qinlan oral liquid can improve the clinical efficacy,reduce the levels of serum inflammatory factors,shorten the time of symptom improvement,and reduce the incidence of adverse reactions of patients with AURI,which is worthy of popularization and application.